Ruxolitinib

Mantle Cell Lymphoma (MCL)

Ruijin HospitalSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

26 Active assets in the Mantle Cell Lymphoma (MCL) cohort.

Asset / Sponsor	Phase	Rating
Rocbrutinib Guangzhou Lupeng Pharmaceutical Company LTD.	Phase 3	BB
Zuberitamab Zhengzhou University	Phase 4	B
Jwcar029 Sun Yat-sen University	Phase 2	CCC
Vesanoid Ruijin Hospital	Phase 2	CCC
Zamtocabtagene Autoleucel Miltenyi Biomedicine GmbH	Phase 2	CCC

View all 30 →

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisDormant

BBB

Indicative ·

73 / 100

disease related to hematopoietic stem cell transplantDormant

BB

Indicative ·

70 / 100

graft versus host diseaseDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.